Prescription Medicines
Melix Cap.
- Product Category
- Treatment for bone and rheumatoid arthritis
- Active Ingredients
- Meloxicam
- Appearance
- A hard capsule with a teal cap and body, containing yellow or pale yellow powder.
- Reimbursement Code
- 648100760
01 / 02
1. Composition and Strength
- Active ingredient: Meloxicam (in-house specification)----7.5mg
- Additives (tar colorant): Blue No. 1, Yellow No. 5, Yellow No. 203
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: cellactose, magnesium stearate, sodium citrate hydrate, corn starch, capsule, povidone
2. Effectiveness
1. Short-term symptomatic treatment in case of acute exacerbation of osteoarthritis (degenerative arthritis) accompanied by pain and ataxia
2. Symptomatic treatment of rheumatoid arthritis
3. Symptomatic treatment of ankylosing spondylitis
3. Dosage and dosage
1. In case of acute worsening of osteoarthritis (degenerative arthritis):
○ Adults: 7.5 mg of meloxicam is administered orally once a day. If symptoms do not improve, the dose can be increased up to 15 mg per day as needed.
2. Rheumatoid arthritis, ankylosing spondylitis:
○ Adults: Administer 15 mg of this drug orally once a day. Depending on the response to treatment, the dose may be reduced to 7.5 mg per day.
This drug should not be administered in excess of 15 mg per day, and should be taken with water or other beverages during meals.
○ For the elderly or those at high risk of increased adverse reactions, treatment is usually started at a dose of 7.5 mg per day.
○ Patients with severe renal failure who have received hemodialysis should not take more than 7.5 mg per day.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance of the measures to be taken if signs and/or symptoms of serious cardiovascular toxicity appear, and administration of this drug should be discontinued if signs or symptoms such as chest pain, shortness of breath, weakness, or stuttering appear.
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions can occur regardless of a history of severe gastrointestinal disease or the presence or absence of prodromal symptoms. These symptoms generally appear more seriously in older people.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
As with other non-steroidal anti-inflammatory drugs, caution is required in patients with a history of gastrointestinal disease and patients receiving anticoagulants. While taking this drug, patients with gastrointestinal symptoms or a history of gastrointestinal diseases (e.g., ulcerative colitis, Crohn's disease) in particular should be carefully monitored for symptoms and signs of digestive dysfunction, gastrointestinal ulcers, or bleeding. If serious gastrointestinal adverse reactions such as peptic ulcers or gastrointestinal bleeding are suspected, additional evaluation and treatment should be performed immediately. Discontinuation of administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal adverse reactions are completely ruled out may also be a treatment option. There is. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
4) It is known that the administration of non-steroidal anti-inflammatory drugs, including this drug, may cause severe skin reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), and serious hypersensitivity reactions that are life-threatening (e.g., anaphylactic reaction). In patients who report skin/mucosal adverse reactions, special caution should be exercised and discontinuation of this drug should be considered.
5) Non-steroidal anti-inflammatory drugs may rarely cause interstitial nephritis, glomerulonephritis, renal medullary necrosis, and nephrotic syndrome.
6) As with most non-steroidal anti-inflammatory drugs, sometimes increases in serum transaminases or other liver function values, and increases in plasma creatinine and blood urea nitrogen have been reported. In most cases, these levels temporarily rise slightly above normal levels, but if they become severe or persist, this drug should be discontinued and appropriate tests should be performed. For clinically stable patients with cirrhosis, no dose adjustment is necessary.
7) Like other prostaglandin synthesis inhibitors, this drug reduces fertility, so it should not be used in women planning to become pregnant. Women who have difficulty conceiving or who are undergoing infertility testing should consider discontinuing this drug.
2. Do not administer to the following patients (cases).
1) Patients with hypersensitivity to this drug or its components
2) Patients with cross-hypersensitivity to aspirin and other non-steroidal anti-inflammatory drugs
3) Patients with a history of asthma, rhinitis, angioedema, urticaria, or allergic reactions due to aspirin and other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactic reactions after administration of non-steroidal anti-inflammatory drugs have been rarely reported.)
4) Patients with a history of gastrointestinal bleeding or perforation due to previous treatment with nonsteroidal antipyretic analgesics
5) Patients with active gastrointestinal ulcer/perforation or a history of its recurrence
6) Patients with gastrointestinal bleeding, cerebrovascular bleeding, or confirmed systemic bleeding disorder
7) Patients with severe hepatic impairment
8) Patients with severe renal impairment who do not undergo hemodialysis
9) Patients with severe uncontrolled heart failure
10) Patients with severe hypertension
11) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
12) Youth under 15 years of age
13) Pregnant women, women who may be pregnant, or lactating women
14) Patients with inflammatory bowel disease such as Crohn's disease or ulcerative colitis
15) Patients with severe blood abnormalities
16) Women planning to become pregnant (fertility may decrease)
17) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
3. Administer with caution to the following patients.
1) Patients with a history of esophagitis, gastritis, or gastrointestinal ulcers
2) Patients with a history of gastrointestinal bleeding
3) Patients who develop adverse skin reactions (e.g. mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), exfoliative dermatitis)
4) Elderly people
5) Drivers and machine operators
6) Functional renal failure: NSAIDs inhibit the vasodilatory effect of renal prostaglandins and may reduce glomerular filtration, causing functional renal failure. These adverse reactions are dose dependent. Patients with the following risk factors require careful observation of the degree of diuresis and renal function when starting treatment or after increasing the dose.
(1) Elderly people
(2) Concurrent administration of drugs such as ACE inhibitors, angiotensin-II receptor antagonists, and diuretics
(3) Hypovolemia
(4) Patients with congestive heart failure or fluid retention
(5) Patients with renal failure
(6) Patients with nephrotic syndrome
(7) Patients with lupus nephropathy
(8) Patients with hepatic impairment
(9) Patients with high blood pressure
(10) Patients immediately after major surgery accompanied by body fluid loss
7) Patients with blood coagulation disorders or taking anticoagulants
8) Patients with blood abnormalities or a history of them (hematological abnormalities may worsen or recur)
9) Bronchial asthma patients
10) Patients with ischemic heart disease, peripheral artery disease, cerebrovascular disease, or patients with a history of such diseases
11) Patients with risk factors for cardiovascular disease (e.g. high blood pressure, hyperlipidemia, diabetes, smoking)
12) Patients who have had digestive ulcers due to past long-term administration of non-steroidal anti-inflammatory drugs, and who require long-term administration of this drug and are concurrently receiving peptic ulcer treatment with misoprostol (some peptic ulcers are resistant to treatment with misoprostol, so sufficiently observe the progress while taking this drug).
13) Patients with hepatic impairment or its history
14) Patients with renal impairment or its history
15) Patients with heart failure or its history
16) This drug contains Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
4. Adverse reactions
1) Blood and lymphatic system: Aplastic anemia, bone marrow suppression, sometimes changes in blood cell count (including leukocytes), decreased leukocytes, thrombocytopenia, anemia, decreased plasma iron, decreased hemoglobin, decreased hematocrit, increased neutrophils, increased eosinophils, increased basophils, increased monocytes, agranulocytosis, etc. In particular, drugs that may cause bone marrow toxicity such as methotrexate Coadministration may more easily cause agranulocytosis.
2) Immune system: Rarely anaphylaxis, anaphylactoid reactions (including shock) and other immediate hypersensitivity reactions.
3) Mental system: Sometimes dysphoria, rarely confusion, disorientation, mood altered, mood disorder, insomnia, nightmares. Anxiety, increased appetite, depression and nervousness
4) Nervous system: Occasional dizziness, drowsiness, headache, light-headedness, fatigue, drowsiness, taste dysfunction, mental confusion, convulsions, paresthesia, tremor.
5) Eyes: Rarely, visual impairment including blurred vision, conjunctivitis, foreign body sensation in the eye, and scleral hemorrhage in the eye.
6) Ears and inner ear: Sometimes tinnitus, rarely dizziness
7) Cardiovascular system: Occasional palpitations, increased blood pressure, rarely flushing/facial flushing, arrhythmia, tachycardia, hypotension, hypertension, myocardial infarction, angina pectoris, heart failure, vasculitis.
8) Respiratory system: Occasionally cough, upper respiratory tract infection, rarely asthma, bronchospasm, and difficulty breathing may occur. Also, allergic reactions to aspirin and other non-steroidal anti-inflammatory drugs.
9) Digestive system: Indigestion, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea, sometimes loss of appetite, peptic ulcer, occult or gross gastrointestinal bleeding, stomatitis, gastritis, esophagitis, burping, dry mouth, dry mouth, angular stomatitis, occult bloody stool. In rare cases, gastrointestinal perforation, colitis, gastritis, pancreatitis, melena, and perforated peptic ulcer may occur. Additionally, these adverse reactions are more serious in elderly patients. When gastrointestinal perforation, ulcers, or gastrointestinal bleeding occur, recovery occurs when the drug is stopped, but some patients have died when the drug is re-administered.
10) Liver: Sometimes hepatitis, transient changes in liver function values such as elevation of plasma transaminase concentration or bilirubin, rarely jaundice and liver failure.
11) Skin and mucous membranes: alopecia, increased sweating, occasional skin rash, urticaria, itching, rarely mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), angioedema, bullous dermatitis, erythema multiforme, photosensitivity reaction, contact dermatitis, infrequent fixed drug eruption (FDE).
12) Kidney and urinary system: Related to the use of non-steroidal anti-inflammatory drugs, urinary disorders including urinary retention, sometimes changes in renal function values such as increased plasma creatinine level and urea level, decrease in total protein and albumin, proteinuria, urinary sugar, increase in urine sediment, urinary occult blood, sodium and water retention, hyperkalemia, rarely acute renal failure, decrease in urine output, frequent urination, urinary infection, interstitial nephritis.
13) Whole body: Occasionally edema, lower extremity edema, malaise, rarely fever, facial edema, fainting, weight loss, weight gain, armpit/breast pain, etc.
14) Musculoskeletal system: Occasionally joint pain, back pain, armpit/chest pain, stiffness, lower limb weakness
15) Endocrine system: Decrease in female reproductive ability
16) Metabolism and nutrition: rarely dehydration
5. Generalism
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. Since the possibility of adverse reactions increases with increase in dose and administration period, this drug is administered at the lowest effective dose for the shortest possible period to match the treatment purpose of each patient.
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
3) When using for chronic diseases, consider the following:
(1) In case of long-term administration: Conduct regular clinical tests (urinalysis, blood tests such as complete blood count (CBC) and physicochemical tests, liver function tests, fecal occult blood tests, etc.), and if abnormalities are found, take appropriate measures such as reducing the dose or stopping medication. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
(2) Treatments other than drug therapy are also considered.
4) When used for acute diseases, administer considering the following.
(1) Administer considering the degree of acute inflammation, pain, and fever.
(2) In principle, long-term administration of the same drug should be avoided.
(3) If there is a causative treatment, implement it.
5) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions.
6) Gastrointestinal adverse reactions: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
7) High blood pressure: Non-steroidal anti-inflammatory drugs, including this drug, may cause heart failure or high blood pressure or worsen existing heart failure or high blood pressure, which may increase the incidence of adverse cardiovascular events. Clinical monitoring is required for patients at this risk. When patients taking thiazide diuretics or loop diuretics take NSAIDs, the response to these therapies may be reduced, as they interfere with the diuretic's effect of increasing sodium excretion. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
8) Congestive heart failure and edema: NSAIDs can induce retention of potassium, sodium, and water. Fluid retention and edema have been observed in some patients taking nonsteroidal anti-inflammatory drugs, including this drug. This drug may worsen heart failure, so clinical observation is required and it should be administered with caution in patients with fluid retention or heart failure.
9) Hyperkalemia may occur when this drug is administered to diabetic patients or in combination with drugs that increase blood potassium levels, so regular monitoring of potassium levels is necessary in these cases.
10) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. In particular, in patients with reduced renal blood flow and blood volume, the administration of non-steroidal anti-inflammatory drugs may cause obvious renal metabolic abnormalities. Because the role of prostaglandins is important in maintaining renal blood flow, elderly patients, dehydrated patients, patients with congestive heart failure, cirrhosis, liver failure, nephrotic syndrome, patients with overt renal disease, patients with renal failure, patients receiving diuretics or ACE inhibitors, or patients who have undergone major surgery to reduce blood volume are exposed to this risk and require special attention. When administering drugs to these patients, the degree of diuresis and renal function must be closely monitored. When medication is stopped, most cases return to their pre-treatment state.
11) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
12) For patients with severe renal failure on dialysis, the dose should not exceed 7.5 mg, and in the case of mild and moderate renal failure (creatinine clearance > 25 mL/min), there is no need to adjust the dose.
13) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or for patients with abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g., eosinophilia, rash) appear, administration of this drug should be discontinued.
14) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
15) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactic reaction occurs, emergency treatment must be administered.
16) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome), which can be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin manifestations and symptoms and should discontinue medication at the first signs and symptoms of skin rash, mucous membrane damage, or other hypersensitivity reactions. Additionally, cases of fixed drug eruption (FDE) have been reported related to meloxicam. Meloxicam should not be re-administered to patients with a history of meloxicam-related FDE, and cross-reactions with other oxicam products (oxicams) may occur.
17) Some asthma patients may be sensitive to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
18) Before starting treatment with this drug, ensure that the history of esophagitis, gastritis, and/or gastrointestinal ulcers has been completely treated.
19) Even if the treatment effect is insufficient, the maximum daily dose should not be exceeded or other non-steroidal anti-inflammatory analgesics should be taken additionally. In this case, the therapeutic effect is not known, but adverse reactions may increase.
20) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroid administration may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
21) Due to the pharmacological properties of this drug, it can mask the symptoms of infectious diseases by making other symptoms and signs of inflammation invisible and delay the diagnosis of infectious complications under painful and non-infectious conditions.
22) No special studies have been conducted on the effect of this drug on machine operation or driving ability. However, if visual impairment, drowsiness, dizziness, or other central nervous system abnormalities occur after taking this medicine, do not operate machinery or drive.
23) Temporary infertility has been reported in women taking nonsteroidal anti-inflammatory drugs for a long time.
24) Patients taking non-steroidal anti-inflammatory drugs for a long period of time should have a complete blood count (CBC) and physicochemical tests performed regularly. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
6. Interaction
1) Concurrent administration with other prostaglandin synthesis inhibitors (including glucocorticoids and aspirin): Concurrent administration with prostaglandin synthesis inhibitors is not recommended as the risk of gastrointestinal ulcers and bleeding may increase due to synergistic effects. In particular, do not administer in combination with other non-steroidal anti-inflammatory drugs because the risk of adverse reactions may increase. When co-administered with aspirin at 1000 mg three times daily in healthy volunteers, the AUC (10%) and Cmax (24%) of the drug tended to increase. The clinical significance of the interaction is unknown.
2) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic reactions associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
3) Coumarin anticoagulants (warfarin, etc.), heparin, ticlopidin, antiplatelet agents, thrombolytics, and selective serotonin reuptake inhibitors (SSRIs): When administered together, the risk of bleeding (including severe gastrointestinal bleeding) may increase compared to when administered alone by inhibiting platelet function and damaging the gastroduodenal mucosa. Patients taking these drugs together should carefully monitor the action of anticoagulants if concurrent use is unavoidable.
4) Lithium: It has been reported that non-steroidal anti-inflammatory drugs increase plasma lithium levels to the point of toxicity by reducing renal excretion of lithium. Therefore, co-administration of lithium and this drug is not recommended. If co-administration is necessary, plasma lithium levels should be monitored during initial administration, dose adjustment, and when administration is discontinued, and signs of toxicity should be carefully observed.
5) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs reduces the tubular secretion of methotrexate, increasing the plasma concentration of methotrexate, which increases the hematological toxicity of methotrexate. Therefore, this drug and high doses of methotrexate (more than 15 mg/week) should not be co-administered. If co-administration is necessary, it should be administered carefully with low doses of methotrexate while closely monitoring blood cell counts and renal function. Agranulocytosis may occur.
6) Diuretics: Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidneys. Because it causes rapid dehydration when used in combination with diuretics, renal function should be measured prior to starting administration and signs of renal failure should be closely observed during combined administration.
7) Antihypertensive drugs (beta blockers, ACE inhibitors, angiotensin II receptor antagonists, vasodilators): NSAIDs reduce the antihypertensive effect of beta blockers, ACE inhibitors, and angiotensin II receptor antagonists, so these interactions should be kept in mind when administered together with this drug.
8) Non-steroidal anti-inflammatory drugs synergistically reduce the glomerular filtration rate when administered in combination with angiotensin II receptor antagonists as well as ACE inhibitors. Patients with preexisting renal function decline are at risk of developing acute renal failure.
9) There are reports that non-steroidal anti-inflammatory drugs reduce the effectiveness of intrauterine contraceptive devices.
10) When administered in combination with cholestyramine, the effect of this drug may be reduced because it adsorbs with this drug in the gastrointestinal tract and increases the elimination rate.
11) Cyclosporine and tacrolimus: Since nephrotoxicity may increase with concurrent administration with non-steroidal anti-inflammatory drugs, renal function should be measured during concurrent administration.
12) When co-administered with antacids, cimetidine, or digoxin, there was no effect on the pharmacokinetic interaction of this drug.
13) Meloxicam is almost always metabolized and excreted in the liver. Of these, 2/3 are metabolized by CYP-450 enzymes, and the remaining 1/3 are metabolized through other pathways, such as oxidation by peroxidase. Therefore, pharmacokinetic interactions may occur when meloxicam is coadministered with drugs that are metabolized by or known to inhibit CYP-450.
14) The effect of this drug may increase when administered concurrently with oral hypoglycemic agents.
15) When administered together with quinidine, the effect of this drug may be reduced.
16) Pentoxifylline: The risk of bleeding may increase when administered together with this drug.
17) Zidovudine: Hematological toxicity (severe anemia and intraerythrocyte toxicity) may increase when administered in combination with non-steroidal anti-inflammatory drugs. Complete blood count and reticulocyte count should be measured 8 to 15 days after administration of nonsteroidal anti-inflammatory drugs.
18) Probenecid, Sulfinpyrazone: When administered together, the blood concentration of this drug increases and the half-life in the blood is prolonged, so administer with caution, including reducing the dose.
19) Alcohol: In particular, adverse reactions in the gastrointestinal tract or central nervous system may be enhanced.
7. Administration to pregnant and lactating women
1) This drug should not be administered during pregnancy.
Inhibition of prostaglandin synthesis may have negative effects on pregnancy and/or embryo-fetal formation. Epidemiological studies have shown that the risk of miscarriage, cardiac malformation, and gastroschisis increases after using prostaglandin synthesis inhibitors in early pregnancy. The absolute risk of cardiovascular malformations increased from less than 1% to almost 1.5%. This risk appears to increase with dose and duration of treatment. Animal testing results showed that taking prostaglandin synthesis inhibitors increased peri-implantation loss and embryo-fetal mortality. Additionally, an increase in the occurrence of various malformations, including cardiovascular, was reported in animals administered prostaglandin synthesis inhibitors during organogenesis.
During the last three months of pregnancy, all prostaglandin synthesis inhibitors can cause the following symptoms in the fetus:
- Cardiopulmonary toxicity (with premature occlusion of the ductus arteriosus and pulmonary hypertension)
- It may cause renal dysfunction in mothers, newborns, and pregnant women in the last trimester of pregnancy, and renal dysfunction may progress to renal failure accompanied by oligo-hydromniasis.
- Possibility of prolongation of bleeding time, anti-coagulant effect may occur even at very low doses.
- Delay or prolongation of labor as a result of inhibition of uterine contractions
2) It is not known whether this drug is secreted into human breast milk, but animal experiments confirmed that this drug is secreted into breast milk, and many non-steroidal anti-inflammatory analgesics are known to pass into human breast milk, so it should not be administered to nursing mothers.
8. Administration to elderly people
Elderly people have weak renal, liver, and cardiac functions, so administer the drug with caution in the minimum necessary dose and pay particular attention to the occurrence of adverse reactions.
9. Treatment in case of overdose
1) Symptoms: When overdosing on non-steroidal anti-inflammatory drugs, symptoms are usually limited to drowsiness, nausea, vomiting, and pain in the solar plexus, and gastrointestinal bleeding may occur. Severe poisoning can cause hypertension, acute renal failure, liver failure, respiratory depression, coma, convulsions, cardiovascular collapse, and cardiac arrest.
2) Treatment: There is no known antidote for this drug, so in case of overdose, gastric lavage and general supportive care are performed. It is recommended to use activated charcoal within 1-2 hours after overdose. Clinical trials have shown that oral administration of 4 g of cholestyramine three times a day promotes the excretion of this drug. Special treatments such as compulsive diuresis, urine alkalinization, dialysis, or hemodialysis do not help eliminate NSAIDs due to their high protein binding and extensive metabolism.
10. Precautions for storage and handling
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause an accident due to misuse of the medicine or cause a decrease in the quality of the medicine, so keep it in the original container and keep it tightly closed.
5. How to save
Store in a light-proof, airtight container at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle, 100 capsules/bottle
7. Period of use
24 months from date of manufacture
- Active ingredient: Meloxicam (in-house specification)----7.5mg
- Additives (tar colorant): Blue No. 1, Yellow No. 5, Yellow No. 203
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: cellactose, magnesium stearate, sodium citrate hydrate, corn starch, capsule, povidone
2. Effectiveness
1. Short-term symptomatic treatment in case of acute exacerbation of osteoarthritis (degenerative arthritis) accompanied by pain and ataxia
2. Symptomatic treatment of rheumatoid arthritis
3. Symptomatic treatment of ankylosing spondylitis
3. Dosage and dosage
1. In case of acute worsening of osteoarthritis (degenerative arthritis):
○ Adults: 7.5 mg of meloxicam is administered orally once a day. If symptoms do not improve, the dose can be increased up to 15 mg per day as needed.
2. Rheumatoid arthritis, ankylosing spondylitis:
○ Adults: Administer 15 mg of this drug orally once a day. Depending on the response to treatment, the dose may be reduced to 7.5 mg per day.
This drug should not be administered in excess of 15 mg per day, and should be taken with water or other beverages during meals.
○ For the elderly or those at high risk of increased adverse reactions, treatment is usually started at a dose of 7.5 mg per day.
○ Patients with severe renal failure who have received hemodialysis should not take more than 7.5 mg per day.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance of the measures to be taken if signs and/or symptoms of serious cardiovascular toxicity appear, and administration of this drug should be discontinued if signs or symptoms such as chest pain, shortness of breath, weakness, or stuttering appear.
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions can occur regardless of a history of severe gastrointestinal disease or the presence or absence of prodromal symptoms. These symptoms generally appear more seriously in older people.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
As with other non-steroidal anti-inflammatory drugs, caution is required in patients with a history of gastrointestinal disease and patients receiving anticoagulants. While taking this drug, patients with gastrointestinal symptoms or a history of gastrointestinal diseases (e.g., ulcerative colitis, Crohn's disease) in particular should be carefully monitored for symptoms and signs of digestive dysfunction, gastrointestinal ulcers, or bleeding. If serious gastrointestinal adverse reactions such as peptic ulcers or gastrointestinal bleeding are suspected, additional evaluation and treatment should be performed immediately. Discontinuation of administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal adverse reactions are completely ruled out may also be a treatment option. There is. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
4) It is known that the administration of non-steroidal anti-inflammatory drugs, including this drug, may cause severe skin reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), and serious hypersensitivity reactions that are life-threatening (e.g., anaphylactic reaction). In patients who report skin/mucosal adverse reactions, special caution should be exercised and discontinuation of this drug should be considered.
5) Non-steroidal anti-inflammatory drugs may rarely cause interstitial nephritis, glomerulonephritis, renal medullary necrosis, and nephrotic syndrome.
6) As with most non-steroidal anti-inflammatory drugs, sometimes increases in serum transaminases or other liver function values, and increases in plasma creatinine and blood urea nitrogen have been reported. In most cases, these levels temporarily rise slightly above normal levels, but if they become severe or persist, this drug should be discontinued and appropriate tests should be performed. For clinically stable patients with cirrhosis, no dose adjustment is necessary.
7) Like other prostaglandin synthesis inhibitors, this drug reduces fertility, so it should not be used in women planning to become pregnant. Women who have difficulty conceiving or who are undergoing infertility testing should consider discontinuing this drug.
2. Do not administer to the following patients (cases).
1) Patients with hypersensitivity to this drug or its components
2) Patients with cross-hypersensitivity to aspirin and other non-steroidal anti-inflammatory drugs
3) Patients with a history of asthma, rhinitis, angioedema, urticaria, or allergic reactions due to aspirin and other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactic reactions after administration of non-steroidal anti-inflammatory drugs have been rarely reported.)
4) Patients with a history of gastrointestinal bleeding or perforation due to previous treatment with nonsteroidal antipyretic analgesics
5) Patients with active gastrointestinal ulcer/perforation or a history of its recurrence
6) Patients with gastrointestinal bleeding, cerebrovascular bleeding, or confirmed systemic bleeding disorder
7) Patients with severe hepatic impairment
8) Patients with severe renal impairment who do not undergo hemodialysis
9) Patients with severe uncontrolled heart failure
10) Patients with severe hypertension
11) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
12) Youth under 15 years of age
13) Pregnant women, women who may be pregnant, or lactating women
14) Patients with inflammatory bowel disease such as Crohn's disease or ulcerative colitis
15) Patients with severe blood abnormalities
16) Women planning to become pregnant (fertility may decrease)
17) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
3. Administer with caution to the following patients.
1) Patients with a history of esophagitis, gastritis, or gastrointestinal ulcers
2) Patients with a history of gastrointestinal bleeding
3) Patients who develop adverse skin reactions (e.g. mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), exfoliative dermatitis)
4) Elderly people
5) Drivers and machine operators
6) Functional renal failure: NSAIDs inhibit the vasodilatory effect of renal prostaglandins and may reduce glomerular filtration, causing functional renal failure. These adverse reactions are dose dependent. Patients with the following risk factors require careful observation of the degree of diuresis and renal function when starting treatment or after increasing the dose.
(1) Elderly people
(2) Concurrent administration of drugs such as ACE inhibitors, angiotensin-II receptor antagonists, and diuretics
(3) Hypovolemia
(4) Patients with congestive heart failure or fluid retention
(5) Patients with renal failure
(6) Patients with nephrotic syndrome
(7) Patients with lupus nephropathy
(8) Patients with hepatic impairment
(9) Patients with high blood pressure
(10) Patients immediately after major surgery accompanied by body fluid loss
7) Patients with blood coagulation disorders or taking anticoagulants
8) Patients with blood abnormalities or a history of them (hematological abnormalities may worsen or recur)
9) Bronchial asthma patients
10) Patients with ischemic heart disease, peripheral artery disease, cerebrovascular disease, or patients with a history of such diseases
11) Patients with risk factors for cardiovascular disease (e.g. high blood pressure, hyperlipidemia, diabetes, smoking)
12) Patients who have had digestive ulcers due to past long-term administration of non-steroidal anti-inflammatory drugs, and who require long-term administration of this drug and are concurrently receiving peptic ulcer treatment with misoprostol (some peptic ulcers are resistant to treatment with misoprostol, so sufficiently observe the progress while taking this drug).
13) Patients with hepatic impairment or its history
14) Patients with renal impairment or its history
15) Patients with heart failure or its history
16) This drug contains Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
4. Adverse reactions
1) Blood and lymphatic system: Aplastic anemia, bone marrow suppression, sometimes changes in blood cell count (including leukocytes), decreased leukocytes, thrombocytopenia, anemia, decreased plasma iron, decreased hemoglobin, decreased hematocrit, increased neutrophils, increased eosinophils, increased basophils, increased monocytes, agranulocytosis, etc. In particular, drugs that may cause bone marrow toxicity such as methotrexate Coadministration may more easily cause agranulocytosis.
2) Immune system: Rarely anaphylaxis, anaphylactoid reactions (including shock) and other immediate hypersensitivity reactions.
3) Mental system: Sometimes dysphoria, rarely confusion, disorientation, mood altered, mood disorder, insomnia, nightmares. Anxiety, increased appetite, depression and nervousness
4) Nervous system: Occasional dizziness, drowsiness, headache, light-headedness, fatigue, drowsiness, taste dysfunction, mental confusion, convulsions, paresthesia, tremor.
5) Eyes: Rarely, visual impairment including blurred vision, conjunctivitis, foreign body sensation in the eye, and scleral hemorrhage in the eye.
6) Ears and inner ear: Sometimes tinnitus, rarely dizziness
7) Cardiovascular system: Occasional palpitations, increased blood pressure, rarely flushing/facial flushing, arrhythmia, tachycardia, hypotension, hypertension, myocardial infarction, angina pectoris, heart failure, vasculitis.
8) Respiratory system: Occasionally cough, upper respiratory tract infection, rarely asthma, bronchospasm, and difficulty breathing may occur. Also, allergic reactions to aspirin and other non-steroidal anti-inflammatory drugs.
9) Digestive system: Indigestion, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea, sometimes loss of appetite, peptic ulcer, occult or gross gastrointestinal bleeding, stomatitis, gastritis, esophagitis, burping, dry mouth, dry mouth, angular stomatitis, occult bloody stool. In rare cases, gastrointestinal perforation, colitis, gastritis, pancreatitis, melena, and perforated peptic ulcer may occur. Additionally, these adverse reactions are more serious in elderly patients. When gastrointestinal perforation, ulcers, or gastrointestinal bleeding occur, recovery occurs when the drug is stopped, but some patients have died when the drug is re-administered.
10) Liver: Sometimes hepatitis, transient changes in liver function values such as elevation of plasma transaminase concentration or bilirubin, rarely jaundice and liver failure.
11) Skin and mucous membranes: alopecia, increased sweating, occasional skin rash, urticaria, itching, rarely mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), angioedema, bullous dermatitis, erythema multiforme, photosensitivity reaction, contact dermatitis, infrequent fixed drug eruption (FDE).
12) Kidney and urinary system: Related to the use of non-steroidal anti-inflammatory drugs, urinary disorders including urinary retention, sometimes changes in renal function values such as increased plasma creatinine level and urea level, decrease in total protein and albumin, proteinuria, urinary sugar, increase in urine sediment, urinary occult blood, sodium and water retention, hyperkalemia, rarely acute renal failure, decrease in urine output, frequent urination, urinary infection, interstitial nephritis.
13) Whole body: Occasionally edema, lower extremity edema, malaise, rarely fever, facial edema, fainting, weight loss, weight gain, armpit/breast pain, etc.
14) Musculoskeletal system: Occasionally joint pain, back pain, armpit/chest pain, stiffness, lower limb weakness
15) Endocrine system: Decrease in female reproductive ability
16) Metabolism and nutrition: rarely dehydration
5. Generalism
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. Since the possibility of adverse reactions increases with increase in dose and administration period, this drug is administered at the lowest effective dose for the shortest possible period to match the treatment purpose of each patient.
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
3) When using for chronic diseases, consider the following:
(1) In case of long-term administration: Conduct regular clinical tests (urinalysis, blood tests such as complete blood count (CBC) and physicochemical tests, liver function tests, fecal occult blood tests, etc.), and if abnormalities are found, take appropriate measures such as reducing the dose or stopping medication. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
(2) Treatments other than drug therapy are also considered.
4) When used for acute diseases, administer considering the following.
(1) Administer considering the degree of acute inflammation, pain, and fever.
(2) In principle, long-term administration of the same drug should be avoided.
(3) If there is a causative treatment, implement it.
5) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions.
6) Gastrointestinal adverse reactions: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
7) High blood pressure: Non-steroidal anti-inflammatory drugs, including this drug, may cause heart failure or high blood pressure or worsen existing heart failure or high blood pressure, which may increase the incidence of adverse cardiovascular events. Clinical monitoring is required for patients at this risk. When patients taking thiazide diuretics or loop diuretics take NSAIDs, the response to these therapies may be reduced, as they interfere with the diuretic's effect of increasing sodium excretion. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
8) Congestive heart failure and edema: NSAIDs can induce retention of potassium, sodium, and water. Fluid retention and edema have been observed in some patients taking nonsteroidal anti-inflammatory drugs, including this drug. This drug may worsen heart failure, so clinical observation is required and it should be administered with caution in patients with fluid retention or heart failure.
9) Hyperkalemia may occur when this drug is administered to diabetic patients or in combination with drugs that increase blood potassium levels, so regular monitoring of potassium levels is necessary in these cases.
10) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. In particular, in patients with reduced renal blood flow and blood volume, the administration of non-steroidal anti-inflammatory drugs may cause obvious renal metabolic abnormalities. Because the role of prostaglandins is important in maintaining renal blood flow, elderly patients, dehydrated patients, patients with congestive heart failure, cirrhosis, liver failure, nephrotic syndrome, patients with overt renal disease, patients with renal failure, patients receiving diuretics or ACE inhibitors, or patients who have undergone major surgery to reduce blood volume are exposed to this risk and require special attention. When administering drugs to these patients, the degree of diuresis and renal function must be closely monitored. When medication is stopped, most cases return to their pre-treatment state.
11) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
12) For patients with severe renal failure on dialysis, the dose should not exceed 7.5 mg, and in the case of mild and moderate renal failure (creatinine clearance > 25 mL/min), there is no need to adjust the dose.
13) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or for patients with abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g., eosinophilia, rash) appear, administration of this drug should be discontinued.
14) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
15) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactic reaction occurs, emergency treatment must be administered.
16) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome), which can be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin manifestations and symptoms and should discontinue medication at the first signs and symptoms of skin rash, mucous membrane damage, or other hypersensitivity reactions. Additionally, cases of fixed drug eruption (FDE) have been reported related to meloxicam. Meloxicam should not be re-administered to patients with a history of meloxicam-related FDE, and cross-reactions with other oxicam products (oxicams) may occur.
17) Some asthma patients may be sensitive to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
18) Before starting treatment with this drug, ensure that the history of esophagitis, gastritis, and/or gastrointestinal ulcers has been completely treated.
19) Even if the treatment effect is insufficient, the maximum daily dose should not be exceeded or other non-steroidal anti-inflammatory analgesics should be taken additionally. In this case, the therapeutic effect is not known, but adverse reactions may increase.
20) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroid administration may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
21) Due to the pharmacological properties of this drug, it can mask the symptoms of infectious diseases by making other symptoms and signs of inflammation invisible and delay the diagnosis of infectious complications under painful and non-infectious conditions.
22) No special studies have been conducted on the effect of this drug on machine operation or driving ability. However, if visual impairment, drowsiness, dizziness, or other central nervous system abnormalities occur after taking this medicine, do not operate machinery or drive.
23) Temporary infertility has been reported in women taking nonsteroidal anti-inflammatory drugs for a long time.
24) Patients taking non-steroidal anti-inflammatory drugs for a long period of time should have a complete blood count (CBC) and physicochemical tests performed regularly. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
6. Interaction
1) Concurrent administration with other prostaglandin synthesis inhibitors (including glucocorticoids and aspirin): Concurrent administration with prostaglandin synthesis inhibitors is not recommended as the risk of gastrointestinal ulcers and bleeding may increase due to synergistic effects. In particular, do not administer in combination with other non-steroidal anti-inflammatory drugs because the risk of adverse reactions may increase. When co-administered with aspirin at 1000 mg three times daily in healthy volunteers, the AUC (10%) and Cmax (24%) of the drug tended to increase. The clinical significance of the interaction is unknown.
2) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic reactions associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
3) Coumarin anticoagulants (warfarin, etc.), heparin, ticlopidin, antiplatelet agents, thrombolytics, and selective serotonin reuptake inhibitors (SSRIs): When administered together, the risk of bleeding (including severe gastrointestinal bleeding) may increase compared to when administered alone by inhibiting platelet function and damaging the gastroduodenal mucosa. Patients taking these drugs together should carefully monitor the action of anticoagulants if concurrent use is unavoidable.
4) Lithium: It has been reported that non-steroidal anti-inflammatory drugs increase plasma lithium levels to the point of toxicity by reducing renal excretion of lithium. Therefore, co-administration of lithium and this drug is not recommended. If co-administration is necessary, plasma lithium levels should be monitored during initial administration, dose adjustment, and when administration is discontinued, and signs of toxicity should be carefully observed.
5) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs reduces the tubular secretion of methotrexate, increasing the plasma concentration of methotrexate, which increases the hematological toxicity of methotrexate. Therefore, this drug and high doses of methotrexate (more than 15 mg/week) should not be co-administered. If co-administration is necessary, it should be administered carefully with low doses of methotrexate while closely monitoring blood cell counts and renal function. Agranulocytosis may occur.
6) Diuretics: Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidneys. Because it causes rapid dehydration when used in combination with diuretics, renal function should be measured prior to starting administration and signs of renal failure should be closely observed during combined administration.
7) Antihypertensive drugs (beta blockers, ACE inhibitors, angiotensin II receptor antagonists, vasodilators): NSAIDs reduce the antihypertensive effect of beta blockers, ACE inhibitors, and angiotensin II receptor antagonists, so these interactions should be kept in mind when administered together with this drug.
8) Non-steroidal anti-inflammatory drugs synergistically reduce the glomerular filtration rate when administered in combination with angiotensin II receptor antagonists as well as ACE inhibitors. Patients with preexisting renal function decline are at risk of developing acute renal failure.
9) There are reports that non-steroidal anti-inflammatory drugs reduce the effectiveness of intrauterine contraceptive devices.
10) When administered in combination with cholestyramine, the effect of this drug may be reduced because it adsorbs with this drug in the gastrointestinal tract and increases the elimination rate.
11) Cyclosporine and tacrolimus: Since nephrotoxicity may increase with concurrent administration with non-steroidal anti-inflammatory drugs, renal function should be measured during concurrent administration.
12) When co-administered with antacids, cimetidine, or digoxin, there was no effect on the pharmacokinetic interaction of this drug.
13) Meloxicam is almost always metabolized and excreted in the liver. Of these, 2/3 are metabolized by CYP-450 enzymes, and the remaining 1/3 are metabolized through other pathways, such as oxidation by peroxidase. Therefore, pharmacokinetic interactions may occur when meloxicam is coadministered with drugs that are metabolized by or known to inhibit CYP-450.
14) The effect of this drug may increase when administered concurrently with oral hypoglycemic agents.
15) When administered together with quinidine, the effect of this drug may be reduced.
16) Pentoxifylline: The risk of bleeding may increase when administered together with this drug.
17) Zidovudine: Hematological toxicity (severe anemia and intraerythrocyte toxicity) may increase when administered in combination with non-steroidal anti-inflammatory drugs. Complete blood count and reticulocyte count should be measured 8 to 15 days after administration of nonsteroidal anti-inflammatory drugs.
18) Probenecid, Sulfinpyrazone: When administered together, the blood concentration of this drug increases and the half-life in the blood is prolonged, so administer with caution, including reducing the dose.
19) Alcohol: In particular, adverse reactions in the gastrointestinal tract or central nervous system may be enhanced.
7. Administration to pregnant and lactating women
1) This drug should not be administered during pregnancy.
Inhibition of prostaglandin synthesis may have negative effects on pregnancy and/or embryo-fetal formation. Epidemiological studies have shown that the risk of miscarriage, cardiac malformation, and gastroschisis increases after using prostaglandin synthesis inhibitors in early pregnancy. The absolute risk of cardiovascular malformations increased from less than 1% to almost 1.5%. This risk appears to increase with dose and duration of treatment. Animal testing results showed that taking prostaglandin synthesis inhibitors increased peri-implantation loss and embryo-fetal mortality. Additionally, an increase in the occurrence of various malformations, including cardiovascular, was reported in animals administered prostaglandin synthesis inhibitors during organogenesis.
During the last three months of pregnancy, all prostaglandin synthesis inhibitors can cause the following symptoms in the fetus:
- Cardiopulmonary toxicity (with premature occlusion of the ductus arteriosus and pulmonary hypertension)
- It may cause renal dysfunction in mothers, newborns, and pregnant women in the last trimester of pregnancy, and renal dysfunction may progress to renal failure accompanied by oligo-hydromniasis.
- Possibility of prolongation of bleeding time, anti-coagulant effect may occur even at very low doses.
- Delay or prolongation of labor as a result of inhibition of uterine contractions
2) It is not known whether this drug is secreted into human breast milk, but animal experiments confirmed that this drug is secreted into breast milk, and many non-steroidal anti-inflammatory analgesics are known to pass into human breast milk, so it should not be administered to nursing mothers.
8. Administration to elderly people
Elderly people have weak renal, liver, and cardiac functions, so administer the drug with caution in the minimum necessary dose and pay particular attention to the occurrence of adverse reactions.
9. Treatment in case of overdose
1) Symptoms: When overdosing on non-steroidal anti-inflammatory drugs, symptoms are usually limited to drowsiness, nausea, vomiting, and pain in the solar plexus, and gastrointestinal bleeding may occur. Severe poisoning can cause hypertension, acute renal failure, liver failure, respiratory depression, coma, convulsions, cardiovascular collapse, and cardiac arrest.
2) Treatment: There is no known antidote for this drug, so in case of overdose, gastric lavage and general supportive care are performed. It is recommended to use activated charcoal within 1-2 hours after overdose. Clinical trials have shown that oral administration of 4 g of cholestyramine three times a day promotes the excretion of this drug. Special treatments such as compulsive diuresis, urine alkalinization, dialysis, or hemodialysis do not help eliminate NSAIDs due to their high protein binding and extensive metabolism.
10. Precautions for storage and handling
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause an accident due to misuse of the medicine or cause a decrease in the quality of the medicine, so keep it in the original container and keep it tightly closed.
5. How to save
Store in a light-proof, airtight container at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle, 100 capsules/bottle
7. Period of use
24 months from date of manufacture
Product Updates
Total 5items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 5 | Melix Cap. | Precautions for use | 2024.09.13 | PDFMelix Capsule_Change Plan + Change Comparison Table.pdf |
| 4 | Melix Cap. | Melix Capsule (effectiveness, dosage, precautions for use... | 2011.12.29 | HWPMelix Capsule Efficacy and Effect_Usage Dosage_Precautions for Use.hwp |
| 3 | Melix Cap. | Melix Capsule (Precautions for use) | 2011.10.28 | HWPMelix Capsule (Precautions for use).hwp |
| 2 | Melix Cap. | Permission change order (Melix Capsule) (Use... | 2009.10.07 | HWPMelix capsule (precautions for use) change (2009.10.07).hwp |
| 1 | Melix Cap. | Permission change order (Melix Capsule) (Use... | 2008.04.21 | HWPMelix capsule (precautions for use) change (2008.04.21).hwp |